SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2004 / Cilt: 4 - Sayı: 3

Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis

Akut koroner sendromlarda insülin benzeri büyüme faktörü-I ve insülin benzeri büyüme faktörü bağlayıcı protein-3 düzeyleri ve prognozla ilişkisi

Ece ONUR
Özlem ARSLAN
Talat TAVLI
Cevad ŞEKURİ
Özgür BAYTURAN
Ozan ÜTÜK
Uğur Kemal TEZCAN
Pages
209–212
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: We found decreased level of IGF-I only in the STEMI group (105±84 ng/ml vs. 715±150 ng/ml, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the present study was to examine the levels of insulin-like growth factor (IGF-I) and binding protein-3 (IGFBP-3) in acute coronary syndrome (ACS) and their relationship with prognosis.
📊
Key Findings & Data:Methods: Thirty patients with ACS (22 male, 8 female) were included in our study.
💡
Conclusion & Impact:Results: We found decreased level of IGF-I only in the STEMI group (105±84 ng/ml vs. 715±150 ng/ml, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of the present study was to examine the levels of insulin-like growth factor (IGF-I) and binding protein-3 (IGFBP-3) in acute coronary syndrome (ACS) and their relationship with prognosis. Methods: Thirty patients with ACS (22 male, 8 female) were included in our study. Patient’s population included 20 patients with ST elevation myocardial infarction (STEMI) and 10 with non-ST-elevation ACS. Death, re-infarction, revascularization and malignant arrhythmia were monitored during 3 months. Study group was compared with 20 healthy subjects (Controls). Blood samples were collected in the first 24 hours and at the end of third month. Serum IGF-I and IGFBP-3 levels were determined by radioimmunoassay method. Results: We found decreased level of IGF-I only in the STEMI group (105±84 ng/ml vs. 715±150 ng/ml, p

Özet

Amaç: Bu çalışma, serum insülin benzeri büyüme faktörü (İGF-I) ve dolaşımdaki taşıyıcısı olan IGF bağlayıcı protein-3 (İGFBP-3)’ün akut koroner sendromlardaki (AKS) düzeylerinin saptanması ve prognozla ilişkisini araştırmak için planlandı.Yöntem: Çalışmamıza 22’si erkek, 8’i kadın toplam 30 AKS’lu hasta alındı. Hastaların 20’si akut ST yükselmeli miyokard infarktüsü (STEMİ), 10’u ise ST yükselmesiz AKS’lu olgu idi. Olgular 20 sağlıklı birey ile karşılaştırıldı. Olguların ilk 24 saat içinde ve 90. gün olmak üzere 2 kez kan örnekleri alındı. Bütün hastalar 90 gün içinde kardiyovasküler ölüm, re-infarktüs, revaskülarizasyon ve ölümcül aritmiler açısından takip edildi. Serum IGF-I ve IGFBP-3 düzeyleri radyoimmün analizi yöntemi ile ölçüldü. Bulgular: Çalışmamızda, STEMİ grubunda İGF-I düzeyleri, kontrol grubuna göre belirgin olarak azalmış iken (105±84’e ng/ml karşın 715±150 ng/ml, p

🔖

Cite This Article

ONUR, E., ARSLAN, Ö., TAVLI, T., ŞEKURİ, C., BAYTURAN, Ö., ÜTÜK, O., TEZCAN, U. K. (2022). Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis. Anadolu Kardiyoloji Dergisi, Cilt: 4 - Sayı: 3, 209–212. https://ajindex.com/articles/437465

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ferrannini E, Haffner SM, Mitchel BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22
  2. Möller DE, Flier JS. Insulin-resistance mechanisms, syndromes, and implications. N Engl J Med 1991; 325: 938-48
  3. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
  4. Mogul HR, Marshal M, Frey M, et al. Insulin-like growth factor-binding protein-1 as a marker for hyperinsulinemia in obese menopausal women. J Clin Endocrinol Metab 1996; 81: 4492-5
  5. Li Q, Li B, Wang X, et al. Overexpression of insulin-like growth factor-I in mice protects fom myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997; 100: 1991-9
  6. Freestne NS, Ribaric S, Mason WT. The effect of insulin-like growth factor-I on adult rat cardiac contractility. Mol Cell Biochem 1996; 163/164: 223-9
  7. Fan J, Wojnar MM, Theoodorakis M, Lang CH. Regulation of insulin-like growth factor (IGF)-I mRNA and peptide and IGF-binding proteins by interleukin-1. Am J Physiol 1996; 270: R621-9
  8. Lang CH, FarrJ, Cooney R, Vary TC. IL-1 receptor antagonist attenuates sepsis-induced alterations in the IGF system and protein synthesis.Am J Physiol 1996; 270: E430-7
  9. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone. J Mol Cell Cardiol 1999; 31: 2049-61
  10. Moran AM, Colan SD, Majzoub JA, Newburger JW. Exogenous growth hormone: a new therapy for dilated cardiomyopathy. Prog Pediatr Cardiol. 2000; 12: 125-32
  11. Volterrani M, Giustina A, Manelli F, et al. Role of growth hormone in chronic heart failure: therapeutic implications. Ital Heart J 2000; 1: 732-8
  12. Böger RH, Skamira C, Bode-Böger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone defficiency. A double-blind, placebo-controlled study. J Clin Invest 1996; 98: 2706-13
  13. Inishi Y, Okuda T, Arakawa T, Kurokawa K. Insulin attenuates intracellular calcium responses and cell contraction caused by vasoactive agents. Kidney Int 1994; 45: 1318-25
  14. Li B, Setoguchi M, Wang X, et al. Insulin-like growth factor-I attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 1991; 84: 1007-19
  15. Kluge A, Zimmermann R, Weihrauch D, et al. Coordinated expression of the insulin-like growth factor system after microembolisation in porcine hea